Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Jefferies Remains Bullish on Compugen (CGEN) - PT to $9
February 11, 2016 9:46 AM ESTJefferies maintained a Buy rating on Compugen (NASDAQ: CGEN), and cut the price target to $9.00 (from $11.00). CGEN's drug discovery platform has yielded 11 novel immune checkpoint candidate targets, plus five targets for antibody-drug conjugates (ADCs) and four linked to tumour-associated macrophages (TAMs). Jefferies... More
Compugen (CGEN) Tops Q4 EPS by 10c
February 9, 2016 7:10 AM ESTCompugen (NASDAQ: CGEN) reported Q4 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $3.33 million.
For earnings history and earnings-related data on Compugen (CGEN) click here.
... More